

Señora

**Directora de la Dirección de Nuevas Creaciones**

Superintendencia de Industria y Comercio

Ministerio de Comercio, Industria y Turismo

E. S. D.

Re.: Expediente No. **NC2020/0008892**

Solicitud de Patente PCT entrada en Fase Nacional, para:

**“COMPUESTOS DERIVADOS DE TETRAHIDROPIRIDO/OXAZEPINAS,  
COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN Y MÉTODO  
IN VITRO PARA LA INHIBICIÓN DE LA PROTEÍNA QUINASA 1”**

Solicitante: **DENALI THERAPEUTICS INC.**

## **RESPUESTA A OFICIO No. 9442**

Yo, **MARGARITA CASTELLANOS ABONDANO**, mayor de edad, identificada y domiciliada como aparece al pie de mi firma, obrando en mi calidad de apoderada de la sociedad solicitante del asunto citado en la referencia, en atención a su oficio No. **9442** del 04 de agosto de 2020, y para el cual solicite prórroga oportunamente el 31 de agosto de 2020, atentamente me permito dar respuesta al mismo de la siguiente manera:

### **1. Solicitud divisional**

Señala el examinador que la presente solicitud divisional no cumple con el requisito de división literal, por cuanto si bien los compuestos reclamados ya se encontraban incluidos en listados de compuestos reclamados anteriormente, las cinco reivindicaciones de esta solicitud divisional no corresponden a una o más reivindicaciones del capítulo reivindicatorio de la solicitud inicial que hayan sido eliminadas para incluirlas de forma textual y teniendo en cuenta la numeración de las reivindicaciones de forma consecutiva.

Teniendo en cuenta lo anterior, se desea manifestar que, con el fin de obtener la división literal, se ha procedido a modificar voluntariamente el capítulo reivindicatorio de la solicitud inicial, en dos oportunidades: la primera, el 02 de septiembre de 2020, adicionando como nuevas reivindicaciones 53 a 57, las 5 reivindicaciones correspondientes a la presente divisional (de forma consecutiva y reenumerando las dependencias) y la segunda, el pasado 09 de septiembre de 2020, removiendo las mismas reivindicaciones.

De esta manera, puede establecerse que la presente divisional sí representa una división literal de la solicitud inicial, toda vez que las anteriores reivindicaciones 53 a 57 corresponden, de forma literal y consecutiva, a las reivindicaciones 1 a 5 de la presente solicitud divisional. Adicionalmente, teniendo en cuenta que dichas reivindicaciones 53 a 57 fueron removidas de la solicitud inicial, no existe solapamiento de materia entre dicha solicitud inicial y la presente solicitud divisional.

Por otra parte, se desea informar que las reivindicaciones de la presente solicitud divisional fueron corregidas en cuanto a la traducción de algunos términos en inglés, cuando fueron incluidas en la solicitud inicial. Para mejor referencia, se anexa a este escrito, las reivindicaciones como permanecen con su enumeración correspondiente, las cuales se solicita atentamente tener en cuenta para el estudio de patentabilidad.

## 2. Conclusión

Teniendo en cuenta los argumentos que se presentan, es posible establecer que las reivindicaciones del pliego reivindicatorio cumplen con los requerimientos de la Decisión 486.

## 3. Anexos

- Pliego reivindicatorio conformado por cinco (5) reivindicaciones.

Señora Directora,



**Margarita Castellanos Abondano**  
C.C. No. **39.779.654** de Bogotá  
T.P.A. No. **70.819** del C.S.J.  
Calle 117 No. 5A-35 - Bogotá, D.C.  
Teléfono: 7560770










Bogotá, D.C.  
MCA/jms  
P5459  
RESPUESTA AO9442

REIVINDICACIONES

1. Un compuesto que es:










| No. | Estructura | No.  | Estructura |
|-----|------------|------|------------|
| 1   |            | 109B |            |
| 1A  |            |      |            |
| 1B  |            |      |            |
| 2   |            |      |            |
| 3   |            |      |            |
| 4   |            |      |            |
| 5   |            | 113  |            |
| 6   |            | 114A |            |
| 7   |            | 114B |            |











| No. | Estructura | No.  | Estructura |
|-----|------------|------|------------|
| 7A  |            |      |            |
| 7B  |            | 116  |            |
| 8   |            |      |            |
| 9   |            | 118A |            |
| 10  |            | 118B |            |
| 11  |            |      |            |
| 11A |            |      |            |
| 11B |            |      |            |
| 12  |            |      |            |












| No. | Estructura                                                                          | No. | Estructura |
|-----|-------------------------------------------------------------------------------------|-----|------------|
| 12A |    |     |            |
| 12B |    |     |            |
| 13  |    |     |            |
| 14  |   |     |            |
| 15  |  |     |            |
| 16  |  |     |            |
| 17  |  |     |            |
| 18  |  |     |            |
| 19  |  |     |            |



| No. | Estructura | No.  | Estructura |
|-----|------------|------|------------|
| 29  |            |      |            |
| 30  |            |      |            |
| 31  |            |      |            |
| 32  |            |      |            |
| 33  |            |      |            |
| 34  |            |      |            |
| 35  |            | 141A |            |
| 36  |            | 141B |            |
| 37  |            |      |            |

| No. | Estructura                                                                          | No. | Estructura                                                                           |
|-----|-------------------------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------|
| 38A |    |     |                                                                                      |
| 38B |    |     |                                                                                      |
| 39  |   |     |                                                                                      |
| 40  |  |     |                                                                                      |
| 41  |  |     |                                                                                      |
| 42  |  | 147 |  |
| 43  |  |     |                                                                                      |
| 43A |  |     |                                                                                      |
| 44  |  |     |                                                                                      |
| 45  |  |     |                                                                                      |

| No. | Estructura                                                                                                         | No.  | Estructura                                                                           |
|-----|--------------------------------------------------------------------------------------------------------------------|------|--------------------------------------------------------------------------------------|
| 46  |                                   |      |                                                                                      |
| 46A |                                   |      |                                                                                      |
| 46B |                                   |      |                                                                                      |
| 47  |                                  |      |                                                                                      |
| 48  |                                 | 154A |  |
| 49  |                                 | 154B |  |
| 50  |                                 |      |                                                                                      |
| 50A |  <p>Primer isómero eluyente</p> |      |                                                                                      |

| No. | Estructura                                                                                                    | No. | Estructura                                                                           |
|-----|---------------------------------------------------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------|
| 50B | <br>Segundo isómero eluyente |     |                                                                                      |
| 51  |                              |     |                                                                                      |
| 52  |                              |     |                                                                                      |
| 53  |                             |     |                                                                                      |
| 55  |                            |     |                                                                                      |
| 56  |                            |     |                                                                                      |
| 58  |                            | 163 |  |
| 59  |                            | 164 |  |
| 60  |                            |     |                                                                                      |

| No. | Estructura | No.  | Estructura |
|-----|------------|------|------------|
| 60A |            |      |            |
| 60B |            |      |            |
| 61  |            |      |            |
|     |            | 169  |            |
|     |            | 170A |            |
| 64  |            | 170B |            |
| 65  |            |      |            |
| 67A |            | 173  |            |
| 67B |            | 174  |            |

| No. | Estructura | No. | Estructura |
|-----|------------|-----|------------|
| 68A |            | 175 |            |
| 68B |            | 176 |            |
| 69A |            |     |            |
| 69B |            |     |            |
| 70A |            |     |            |
| 70B |            |     |            |
| 71A |            |     |            |
| 71B |            |     |            |
| 72  |            |     |            |

| No. | Estructura | No.  | Estructura |
|-----|------------|------|------------|
|     |            | 181A |            |
|     |            | 181B |            |
|     |            | 183A |            |
| 78  |            | 183B |            |
| 79  |            |      |            |
|     |            | 185  |            |
| 83A |            |      |            |
| 83B |            |      |            |


| No. | Estructura | No. | Estructura |
|-----|------------|-----|------------|
| 84  |            | 193 |            |
| 87  |            |     |            |
| 88  |            |     |            |
| 89A |            |     |            |
| 89B |            |     |            |
| 90A |            | 200 |            |
| 90B |            |     |            |
|     |            | 205 |            |
|     |            | 206 |            |











| No.  | Estructura | No. | Estructura |
|------|------------|-----|------------|
|      |            | 207 |            |
|      |            | 210 |            |
|      |            | 211 |            |
|      |            | 212 |            |
| 101A |            | 214 |            |
| 101B |            |     |            |
|      |            | 216 |            |
| 103A |            |     |            |
| 103B |            |     |            |


| No.  | Estructura | No. | Estructura |
|------|------------|-----|------------|
| 104A |            | 220 |            |
| 104B |            |     |            |
| 105A |            |     |            |
| 105B |            |     |            |
|      |            | 224 |            |
|      |            | 225 |            |
| 109A |            |     |            |











o una sal, profármaco, tautómero, estereoisómero o mezcla de estereoisómeros farmacéuticamente aceptables de los mismos.

2. Un compuesto que es:











































Primer isómero eluyente






















Segundo isómero eluyente















o una sal, profármaco, tautómero, estereoisómero o mezcla de estereoisómeros farmacéuticamente aceptables de los mismos.

3. El compuesto de la reivindicación 2, en donde el compuesto es:



o un estereoisómero o una mezcla de estereoisómeros del mismo, o una sal farmacéuticamente aceptable del mismo.

4. Una composición farmacéutica que comprende un compuesto, o un estereoisómero o una mezcla de estereoisómeros, o una sal farmacéuticamente aceptable del mismo, de las reivindicaciones 1-3 y un excipiente.

5. Un método *in vitro* para inhibir la proteína quinasa 1 que interactúa con el receptor, que comprende poner en contacto una proteína quinasa 1 que interactúa con el receptor con un compuesto, o un estereoisómero o una mezcla de estereoisómeros, o una sal farmacéuticamente aceptable del mismo, de acuerdo con una cualquiera de las reivindicaciones 1-3 o la composición farmacéutica de la reivindicación 4.